(firstQuint)Study of Anlotinib in Patients With Metastatic Colorectal CancermCRC(ALTER0703).

 Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration(SFDA:2011L00661) which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co.

, Ltd.

To compare the effects and safety of Anlotinib with placebo in patients with metastatic colorectal cancer refractory to standard chemotherapies.

.

 Study of Anlotinib in Patients With Metastatic Colorectal CancermCRC(ALTER0703)@highlight

The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with metastatic colorectal cancer refractory to standard chemotherapies.

